Company intelligence / Profile preview
Korea Arlico Pharm
Seoul, Seoul, South Koreaarlico.co.kr ↗
- Ownership
- Private
- Employees
- ~112
- Development stage
- Other
01
Overview
Korea Arlico Pharm is a top 50 Korean pharmaceutical firm with over 30 years history, listed on KOSDAQ since 2018, focused on commercialized generic drugs, with robust domestic and international growth and a PIC/S GMP facility. No original novel clinical-stage assets disclosed, focus is on generics and contract manufacturing.
- Therapeutic areas
- ImmunologyEndocrinologyMetabolic DisordersPsychiatryMen's HealthInfectious DiseasesGastroenterologyHematologyPulmonologyDermatologyCardiovascularNeurology
- Modalities
- Small moleculeGeneric drug
- Industry
- Biotech
02
Drug pipeline
11 assets10 more assets in the full pipeline.
Beyond the preview
Go deeper on Korea Arlico Pharm.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Korea Arlico Pharm.